Director, Radiopharmaceutical Therapy (RPT) Commercialization at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, OncologyIndustries

Requirements

Bachelor’s degree or higher in Life Sciences, pharmacy, business administration or a related field is required; an MBA or advanced degree is beneficial
Minimum of 8-10 years of experience in the pharmaceutical or radiopharmaceutical industry, with a focus on commercialization, market access, or product launch
Radiopharmaceutical experience is required
Experience with early, clinical, and launch assets
Proven track record in developing and executing successful commercialization strategies
Strong analytical skills with the ability to interpret complex data and make strategic decisions
Excellent communication and interpersonal skills

Responsibilities

Partner with our Decision, IT and Analytics team to conduct comprehensive market research and analysis to identify trends, opportunities, and competitive landscape within the radiopharmaceutical sector
Develop and refine the commercialization strategy for the lead radiopharmaceutical assets, including market segmentation, positioning, and value proposition
Evaluate the commercial potential of our pipeline assets and new targets of interest, including target product profiles, market opportunity, access landscape, and revenue forecasts
Collaborate with cross-functional teams, including R&D, regulatory, program management and medical affairs, to ensure alignment of commercialization activities with product development and regulatory timelines
Establish and maintain relationships with key opinion leaders, industry experts, and potential customers to gather insights and support for the product launch and development
Oversee the development of commercialization plans, including budgeting, forecasting, and resource allocation
Monitor and report on commercialization progress, including key performance indicators and market feedback, to inform strategic adjustments

Skills

Oncology Commercialization

Radiopharmaceuticals

RPT

Commercial Strategy

Sales Leadership

Biotechnology

Oncology

Solid Tumors

Targeted Radioisotopes

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free